Home » Stocks » CUE

Cue Biopharma, Inc. (CUE)

Stock Price: $13.00 USD -0.35 (-2.62%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
Market Cap 393.62M
Revenue (ttm) 3.73M
Net Income (ttm) -42.60M
Shares Out 29.65M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $13.00
Previous Close $13.35
Change ($) -0.35
Change (%) -2.62%
Day's Open 13.52
Day's Range 12.95 - 13.86
Day's Volume 151,216
52-Week Range 9.30 - 31.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...

GlobeNewsWire - 1 week ago

Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs

InvestorPlace - 1 month ago

Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.

Other stocks mentioned: GNTY, HCDI, LNDC, PSXP, RILY, VGR
Seeking Alpha - 1 month ago

Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with ...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Cue Biopharma (CUE) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selective...

GlobeNewsWire - 5 months ago

Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development

GlobeNewsWire - 5 months ago

Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined spec...

Zacks Investment Research - 5 months ago

Cue Biopharma (CUE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to sele...

Seeking Alpha - 6 months ago

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

GlobeNewsWire - 6 months ago

CAMBRIDGE, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

Zacks Investment Research - 6 months ago

Cue Biopharma, Inc. (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed...

GlobeNewsWire - 7 months ago

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven...

GlobeNewsWire - 8 months ago

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed...

Seeking Alpha - 9 months ago

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to select...

GlobeNewsWire - 9 months ago

CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to select...

GlobeNewsWire - 9 months ago

Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series

Seeking Alpha - 10 months ago

Dynamic New Players Gain Momentum In Digital, Data And Patient-Centric Space

Other stocks mentioned: EVBG, FVRR
Zacks Investment Research - 10 months ago

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Other stocks mentioned: LVGO, SMED, THMO, VNET
Zacks Investment Research - 10 months ago

A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.

Other stocks mentioned: ATXI, GAIA, PJT, SPTN
Seeking Alpha - 11 months ago

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Cue Biopharma (CUE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 11 months ago

Cue Biopharma, Inc. (CUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Seeking Alpha - 1 year ago

Cue Biopharma: An Innovative But Risky Immunology Pick For 2020

Zacks Investment Research - 1 year ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: FFIN, FMNB, HONE, IBCP
Zacks Investment Research - 1 year ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: HONE, HRZN, IBCP
The Motley Fool - 1 year ago

Concept-proving results for lead programs at these biotechs will send their stock prices soaring or sinking before the year's over.

Other stocks mentioned: CRSP, VRTX
GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

Zacks Investment Research - 1 year ago

U.S. stocks rallied to attained fresh all-time highs in 2019, as the momentum continued in 2020. Here are five stocks that are poised to grow.

Other stocks mentioned: EVER, FLGT, SAVA, TNK
Zacks Investment Research - 1 year ago

Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors?

Zacks Investment Research - 1 year ago

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Other stocks mentioned: ACAD, CGEN, EPZM, QURE
Zacks Investment Research - 1 year ago

Does Cue Biopharma, Inc. (CUE) have what it takes to be a top stock pick for momentum investors?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Cue Biopharma, Inc. (CUE).

Zacks Investment Research - 1 year ago

Cue Biopharma, Inc. (CUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

GlobeNewsWire - 1 year ago

Change represents evolving board capabilities as Cue Biopharma enters next stage of its corporate development Change represents evolving board capabilities as Cue Biopharma enters next stage o...

GlobeNewsWire - 1 year ago

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selec...

GlobeNewsWire - 1 year ago

Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology Company Integrates Operational Oversight with Dr. Suri’s Expertise in Immunology

About CUE

Cue Biopharma, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 frame... [Read more...]

Industry
Biotechnology
IPO Date
Jan 2, 2018
CEO
Daniel Passeri
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
CUE
Full Company Profile

Financial Performance

In 2019, Cue Biopharma's revenue was $3.46 million, an increase of 202.67% compared to the previous year's $1.14 million. Losses were -$36.70 million, -5.85% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Cue Biopharma stock is "Strong Buy." The 12-month stock price forecast is 30.00, which is an increase of 130.77% from the latest price.

Price Target
$30.00
(130.77% upside)
Analyst Consensus: Strong Buy